BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D’Incà R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the clinician. Clin Exp Gastroenterol. 2014;7:151-161. [PMID: 24876789 DOI: 10.2147/ceg.s41413] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Matsuura R, Watanabe O, Nakamura M, Yamamura T, Matsushita M, Suhara H, Furukawa K, Ishikawa T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Hirooka Y, Goto H. Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings. Nagoya J Med Sci 2018;80:257-66. [PMID: 29915443 DOI: 10.18999/nagjms.80.2.257] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Van de Bruaene C, De Looze D, Hindryckx P. Small bowel capsule endoscopy: Where are we after almost 15 years of use? World J Gastrointest Endosc 2015; 7(1): 13-36 [PMID: 25610531 DOI: 10.4253/wjge.v7.i1.13] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 38] [Article Influence: 7.9] [Reference Citation Analysis]
3 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
4 Miot J, Smith S, Bhimsan N. Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective. Int J Clin Pharm 2016;38:880-7. [PMID: 27118462 DOI: 10.1007/s11096-016-0304-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Yoon K, Chang KT, Lee HJ. MRI for Crohn’s Disease: Present and Future. Biomed Res Int. 2015;2015:786802. [PMID: 26413543 DOI: 10.1155/2015/786802] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 MacQueen BC, Christensen RD, Yost CC, Lambert DK, Baer VL, Sheffield MJ, Gordon PV, Cody MJ, Gerday E, Schlaberg R, Lowe J, Shepherd JG. Elevated fecal calprotectin levels during necrotizing enterocolitis are associated with activated neutrophils extruding neutrophil extracellular traps. J Perinatol 2016;36:862-9. [PMID: 27388941 DOI: 10.1038/jp.2016.105] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
7 Kawamura T, Yamamura T, Nakamura M, Maeda K, Sawada T, Ishikawa E, Iida T, Mizutani Y, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M. Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease. Inflamm Bowel Dis 2022:izac076. [PMID: 35436345 DOI: 10.1093/ibd/izac076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kucharski M, Karczewski J, Mańkowska-Wierzbicka D, Karmelita-Katulska K, Kaczmarek E, Iwanik K, Rzymski P, Grzymisławski M, Linke K, Dobrowolska A. Usefulness of Endoscopic Indices in Determination of Disease Activity in Patients with Crohn's Disease. Gastroenterol Res Pract 2016;2016:7896478. [PMID: 26997952 DOI: 10.1155/2016/7896478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Sorrentino D, Gray JM. Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1237-47. [PMID: 33501943 DOI: 10.1093/ibd/izaa348] [Reference Citation Analysis]
10 Eder P, Łykowska-Szuber L, Katulska K, Stawczyk-Eder K, Krela-Kaźmierczak I, Klimczak K, Szymczak A, Stajgis M, Linke K. Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn's disease naive to anti-TNF agents. Prz Gastroenterol 2016;11:187-93. [PMID: 27713781 DOI: 10.5114/pg.2015.55185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
11 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
12 Straksyte V, Kiudelis G, Gineikiene I, Janciauskas D, Basevicius A, Lukosevicius S, Kupcinskas L. Lemann Index for Assessment of Crohn's Disease: Correlation with the Quality of Life, Endoscopic Disease Activity, Magnetic Resonance Index of Activity and C- Reactive Protein. Open Med (Wars) 2019;14:785-91. [PMID: 31737782 DOI: 10.1515/med-2019-0092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Domachevsky L, Leibovitzh H, Avni-Biron I, Lichtenstein L, Goldberg N, Nidam M, Groshar D, Bernstine H, Ben-Bassat O. Correlation of 18F-FDG PET/MRE Metrics with Inflammatory Biomarkers in Patients with Crohn's Disease: A Pilot Study. Contrast Media Mol Imaging 2017;2017:7167292. [PMID: 29097934 DOI: 10.1155/2017/7167292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
14 Sands BE, Irving PM, Hoops T, Izanec JL, Gao L, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, Afzali A, Aitova L, Aldeguer i Mante X, Allez M, Altorjay I, Argüelles Arias F, Armuzzi A, Augustyn M, Bafutto M, Barrio J, Begun J, Behrend C, Bezemer G, Bonnaud G, Brankovic M, Byung IJ, Calvet Calvo X, Chachu K, Chebli JMF, Cheon JH, Cichoz-lach H, Clark L, Cummings F, Dalal K, Danese S, De Boer N, De Lourdes Ferrari M, Désilets E, Dugalic P, Duvall G, Fedorishina O, Filip R, Flores C, Fogel R, Fon J, Frankel M, Friedenberg K, Fries W, Galina V, Gietka P, Goel R, Hasselblatt P, Herfarth H, Herszényi L, Hindryckx P, Hoentjen F, Horjus Talabur Horje C, Iduru S, Irving P, Isfort R, Jairath V, Jones M, Kalimullina D, Katz J, Kaur M, Khurana SK, Kim JS, Kim Y, Kleczkowski D, Knezevic S, Knoll A, Korman LY, Kotzev I, Kulyapin A, Lee KM, Leemreis D, Leszczyszyn J, Limdi J, Lissauer J, Loftus E, Malecka-panas E, Marshall J, Mihály E, Milan L, Monteleone G, Nagorni A, Owczarek D, Palekar N, Panaccione R, Park YS, Park SH, Parra R, Patai Á, Patel K, Patel B, Pershko A, Petrova E, Pineton de Chambrun G, Randall C, Riestra Menendez S, Ritter T, Rivero M, Roblin X, Rocca R, Romatowski J, Rydzewska G, Saibeni S, Salzberg B, Sarles H, Saunders J, Savarino EV, Serclova Z, Shchukina O, Siegel J, Soofi N, Sparrow M, Stokesberry D, Suiter D, Svorcan P, Tkachev A, Tsonev N, Tünde K, Ulbrych J, Vanasek T, Varga M, Vermeire S, Vicente Lidon R, Weiss ML, Wesley E, Winstead N, Wojcik K, Wypych J, Zaltman C, Zdena Z. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet 2022;399:2200-11. [DOI: 10.1016/s0140-6736(22)00688-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cantarelli BCF, de Oliveira RS, Alves AMA, Ribeiro BJ, Velloni F, D'Ippolito G. Evaluating inflammatory activity in Crohn's disease by cross-sectional imaging techniques. Radiol Bras 2020;53:38-46. [PMID: 32313336 DOI: 10.1590/0100-3984.2018.0096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Zhu C, Ma X, Xue L, Xu J, Li Q, Wang Y, Zhang J. Small intestine contrast ultrasonography for the detection and assessment of Crohn disease: A meta-analysis. Medicine (Baltimore) 2016;95:e4235. [PMID: 27495028 DOI: 10.1097/MD.0000000000004235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.2] [Reference Citation Analysis]
17 Sorrentino D, Nguyen VQ, Love K. Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease. Dig Dis 2021;39:626-33. [PMID: 33631768 DOI: 10.1159/000515432] [Reference Citation Analysis]
18 Rocchi C, Soliman YY, Massidda M, Vadalà di Prampero SF, Bulajic M, Sorrentino D. Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review. Dig Dis Sci 2021. [PMID: 34097166 DOI: 10.1007/s10620-021-07002-5] [Reference Citation Analysis]
19 Wang WG, Lu WZ, Yang CM, Yu KQ, He HB. Modified Van Assche magnetic resonance imaging-based score for assessing the clinical status of anal fistulas.Medicine (Baltimore). 2020;99:e20075. [PMID: 32384475 DOI: 10.1097/MD.0000000000020075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zawadka-Kunikowska M, Słomko J, Kłopocka M, Liebert A, Tafil-Klawe M, Klawe JJ, Newton JL, Zalewski P. Cardiac and autonomic function in patients with Crohn's disease during remission. Adv Med Sci 2018;63:334-40. [PMID: 30053718 DOI: 10.1016/j.advms.2018.04.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Masselli G, Mastroiacovo I, De Marco E, Francione G, Casciani E, Polettini E, Gualdi G. Current tecniques and new perpectives research of magnetic resonance enterography in pediatric Crohn’s disease. World J Radiol 2016; 8(7): 668-682 [PMID: 27551337 DOI: 10.4329/wjr.v8.i7.668] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 Zhang Y, Lu C, Zhang J. Lactoferrin and Its Detection Methods: A Review. Nutrients 2021;13:2492. [PMID: 34444652 DOI: 10.3390/nu13082492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Khashper A, Shwartz D, Taragin BH, Shalmon T. Splenic size as a marker for active inflammation in Crohn's disease. Clinical Imaging 2022. [DOI: 10.1016/j.clinimag.2022.02.012] [Reference Citation Analysis]
24 Rubio MG, Amo-Mensah K, Gray JM, Nguyen VQ, Nakat S, Grider D, Love K, Boone JH, Sorrentino D. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol 2019; 10(5): 54-63 [PMID: 31911845 DOI: 10.4291/wjgp.v10.i5.54] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
25 Oliveira AM, Cardoso FS, Rodrigues CG, Santos L, Martins A, de Deus JR, Reis J. Can Red Cell Distribution Width Be Used as a Marker of Crohn's Disease Activity? GE Port J Gastroenterol 2016;23:6-12. [PMID: 28868424 DOI: 10.1016/j.jpge.2015.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
26 Teruel C, Garrido E, Mesonero F. Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther 2016; 7(1): 78-90 [PMID: 26855814 DOI: 10.4292/wjgpt.v7.i1.78] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
27 Gordon M. 5-Aminosalicylates to maintain remission in Crohn’s disease: Interpreting conflicting systematic review evidence. World J Gastrointest Pharmacol Ther 2017; 8(2): 99-102 [PMID: 28533918 DOI: 10.4292/wjgpt.v8.i2.99] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Kyriakidi KS, Tsianos VE, Karvounis E, Christodoulou DK, Katsanos KH, Tsianos EV. Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases. Ann Gastroenterol 2016;29:258-67. [PMID: 27366026 DOI: 10.20524/aog.2016.0028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
29 Bettenworth D, Nowacki TM, Cordes F, Buerke B, Lenze F. Assessment of stricturing Crohn's disease: Current clinical practice and future avenues. World J Gastroenterol 2016; 22(3): 1008-1016 [PMID: 26811643 DOI: 10.3748/wjg.v22.i3.1008] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
30 Jose SK, Simon B, Simon EG, Eapen A, John RA, Putta T, Dutta AK, Pulimood AB. Comparison of Magnetic Resonance Enterography Global Score (MEGS) with indices of Crohn's disease activity in South Asian population. Abdom Radiol (NY) 2022;47:547-53. [PMID: 34958408 DOI: 10.1007/s00261-021-03381-5] [Reference Citation Analysis]
31 Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Dig Endosc 2021;33:1008-23. [PMID: 33020947 DOI: 10.1111/den.13863] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]